Search and analyze individual stocks with comprehensive metrics
Genesis IBRC
Fundamental Score
Genesis IBRC Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of GENESIS across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (51.62%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (51.62%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 24.28 vs Industry: 64.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Excellent EPS Growth (105.89% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (105.89% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
5 factors identified
Profit Decline Concern (-20.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Negative Free Cash Flow (₹-0.33 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Low Promoter Commitment (11.33%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Biotechnology sector...
Financial Statements
Comprehensive financial data for Genesis IBRC
About GENESIS
Company Details
Market Information
Performance
GENESIS Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of GENESIS?
GENESIS is currently trading at ₹64.99 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of GENESIS shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of GENESIS and what does it mean?
GENESIS has a P/E ratio of 24.28x compared to the industry average of 64.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹24 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is GENESIS performing according to Bull Run's analysis?
GENESIS has a Bull Run fundamental score of 41/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 51.62%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does GENESIS belong to?
GENESIS operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Genesis IBRC. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for GENESIS?
GENESIS has an ROE of 51.62%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Genesis IBRC generates profits from shareholders' equity. An ROE of 52% means the company generates ₹52 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is GENESIS's debt-to-equity ratio and what does it indicate?
GENESIS has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. This means the company has ₹0 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is GENESIS's dividend yield and is it a good dividend stock?
GENESIS offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has GENESIS grown over the past 5 years?
GENESIS has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth 105.89%, and EPS Growth 105.89%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in GENESIS and why does it matter?
Promoters hold 11.33% of GENESIS shares, with 0.00% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does GENESIS compare with its industry peers?
GENESIS trades at P/E 24.28x vs industry average 64.77x, with ROE of 51.62% and ROCE of 51.62%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether GENESIS is outperforming its competitive set in profitability, growth, and valuation metrics.
What is GENESIS's market capitalization and what category does it fall into?
GENESIS has a market capitalization of ₹84 crores, making it a Mid-cap stock. Mid-cap stocks balance growth potential with moderate risk. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for GENESIS?
Key ratios for GENESIS: ROE 51.62% (Excellent), ROCE 51.62%, P/E 24.28x, Debt-to-Equity 0.00, Interest Coverage N/Ax. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is GENESIS stock and what is its beta?
GENESIS has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for GENESIS?
GENESIS has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹64.99, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in GENESIS?
Key risks for GENESIS include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.00), and operational challenges. The stock has a Fundamental Score of 41/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is GENESIS's operating profit margin and how has it trended?
GENESIS has a 5-year average Operating Profit Margin (OPM) of N/A%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is GENESIS's quarterly performance in terms of sales and profit growth?
GENESIS's recent quarterly performance shows YoY Sales Growth of N/A% and YoY Profit Growth of -20.00%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in GENESIS?
GENESIS has FII holding of 0.00% and DII holding of 0.00%, totaling 0.00% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.